Summary
Global Markets Direct’s, ‘Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2016’, provides an overview of the Peripheral T-Cell Lymphomas (PTCL) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Peripheral T-Cell Lymphomas (PTCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Peripheral T-Cell Lymphomas (PTCL)
- The report reviews pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Peripheral T-Cell Lymphomas (PTCL) therapeutics and enlists all their major and minor projects
- The report assesses Peripheral T-Cell Lymphomas (PTCL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Peripheral T-Cell Lymphomas (PTCL)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Peripheral T-Cell Lymphomas (PTCL) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AB Science SA
Affimed Therapeutics AG
Bayer AG
Celgene Corporation
CerRx, Inc.
Chipscreen Biosciences Ltd
Eisai Co., Ltd.
Incyte Corporation
Johnson & Johnson
Karyopharm Therapeutics, Inc.
Mundipharma International Ltd
Ono Pharmaceutical Co., Ltd.
Onxeo SA
Pfizer Inc.
Rhizen Pharmaceuticals S.A.
Seattle Genetics, Inc.
Solasia Pharma K.K.
Spectrum Pharmaceuticals, Inc.
TG Therapeutics, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Peripheral T-Cell Lymphomas (PTCL) Overview 9
Therapeutics Development 10
Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) - Overview 10
Peripheral T-Cell Lymphomas (PTCL) - Therapeutics under Development by Companies 11
Peripheral T-Cell Lymphomas (PTCL) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Peripheral T-Cell Lymphomas (PTCL) - Products under Development by Companies 16
Peripheral T-Cell Lymphomas (PTCL) - Companies Involved in Therapeutics Development 18
AB Science SA 18
Affimed Therapeutics AG 19
Bayer AG 20
Celgene Corporation 21
CerRx, Inc. 22
Chipscreen Biosciences Ltd 23
Eisai Co., Ltd. 24
Incyte Corporation 25
Johnson & Johnson 26
Karyopharm Therapeutics, Inc. 27
Mundipharma International Ltd 28
Ono Pharmaceutical Co., Ltd. 29
Onxeo SA 30
Pfizer Inc. 31
Rhizen Pharmaceuticals S.A. 32
Seattle Genetics, Inc. 33
Solasia Pharma K.K. 34
Spectrum Pharmaceuticals, Inc. 35
TG Therapeutics, Inc. 36
Peripheral T-Cell Lymphomas (PTCL) - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
AFM-13 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
belinostat - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
brentuximab vedotin - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
copanlisib hydrochloride - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
CS-055 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
darinaparsin - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
denileukin diftitox - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
fenretinide - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
forodesine hydrochloride - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
lenalidomide - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
masitinib - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
mitoxantrone hydrochloride - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
nivolumab - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
NL-101 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
pralatrexate - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
romidepsin - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
RP-6530 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
ruxolitinib phosphate - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
selinexor - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
SH-7129 - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
temsirolimus - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
TGR-1202 - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
tipifarnib - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
Peripheral T-Cell Lymphomas (PTCL) - Recent Pipeline Updates 124
Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects 213
Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products 214
Peripheral T-Cell Lymphomas (PTCL) - Product Development Milestones 215
Featured News & Press Releases 215
Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan 215
Dec 07, 2015: Seattle Genetics Highlights ADCETRIS Data Presentations in Frontline Non-Hodgkin Lymphoma at ASH 2015 215
Dec 06, 2015: Spectrum Pharmaceuticals and Onxeo Announce Complete Response in 67% of Patients with Peripheral T-Cell Lymphoma in Combination of Belinostat and Standard CHOP 217
Nov 09, 2015: Onxeo Reports Initial Results of Phase 1 Trial Evaluating Belinostat in Combination with CHOP in Peripheral T-cell Lymphoma 218
Sep 30, 2015: Kura Oncology Initiates Phase 2 Study of Tipifarnib in Peripheral T-cell Lymphoma 220
Jun 23, 2015: Beleodaq (belinostat) pivotal BELIEF study results published in the Journal of Clinical Oncology 220
May 27, 2015: AB Science: Phase 2 with masitinib in peripheral T-cell lymphoma accelerated into phase 3 221
Jan 09, 2015: Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China 223
Dec 09, 2014: Combination of ISTODAX (romidepsin) and Standard CHOP Demonstrates a Complete Response in 51% of Patients with Peripheral T-Cell Lymphoma 223
Dec 05, 2014: Spectrum Pharmaceuticals Highlights Abstracts on Beleodaq (belinostat) at the 56th Annual Meeting of the ASH in San Francisco 224
Appendix 225
Methodology 225
Coverage 225
Secondary Research 225
Primary Research 225
Expert Panel Validation 225
Contact Us 225
Disclaimer 226
List of Tables
Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H1 2016 10
Number of Products under Development by Companies, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Development by Companies, H1 2016 (Contd..1) 17
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by AB Science SA, H1 2016 18
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Affimed Therapeutics AG, H1 2016 19
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Bayer AG, H1 2016 20
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Celgene Corporation, H1 2016 21
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by CerRx, Inc., H1 2016 22
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Chipscreen Biosciences Ltd, H1 2016 23
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Eisai Co., Ltd., H1 2016 24
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Incyte Corporation, H1 2016 25
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Johnson & Johnson, H1 2016 26
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 27
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Mundipharma International Ltd, H1 2016 28
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 29
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Onxeo SA, H1 2016 30
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Pfizer Inc., H1 2016 31
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016 32
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Seattle Genetics, Inc., H1 2016 33
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Solasia Pharma K.K., H1 2016 34
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 35
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by TG Therapeutics, Inc., H1 2016 36
Assessment by Monotherapy Products, H1 2016 37
Number of Products by Stage and Target, H1 2016 39
Number of Products by Stage and Mechanism of Action, H1 2016 42
Number of Products by Stage and Route of Administration, H1 2016 44
Number of Products by Stage and Molecule Type, H1 2016 46
Peripheral T-Cell Lymphomas (PTCL) Therapeutics - Recent Pipeline Updates, H1 2016 124
Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects, H1 2016 213
Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products, H1 2016 214
List of Figures
Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Products, H1 2016 15
Assessment by Monotherapy Products, H1 2016 37
Number of Products by Top 10 Targets, H1 2016 38
Number of Products by Stage and Top 10 Targets, H1 2016 38
Number of Products by Top 10 Mechanism of Actions, H1 2016 41
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 41
Number of Products by Routes of Administration, H1 2016 43
Number of Products by Stage and Routes of Administration, H1 2016 43
Number of Products by Molecule Types, H1 2016 45
Number of Products by Stage and Molecule Types, H1 2016 45
